Učitavanje...
Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
Human cytomegalovirus (HCMV) infection is associated with severe morbidity and mortality in immunocompromised individuals, mainly transplant recipients and AIDS patients, and is the most frequent cause of congenital malformations in newborn children. To date, few drugs are licensed for the treatment...
Spremljeno u:
| Izdano u: | Pharmacol Ther |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier Inc.
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7112563/ https://ncbi.nlm.nih.gov/pubmed/21570424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2011.04.007 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|